Orcosa Appoints Andrew C. von Eschenbach, M.D. and Former Commissioner of the FDA, as Senior Advisor

In his role, Eschenbach will provide strategic counsel on regulatory and public affairs, clinical trial development, and other corporate matters.

EWING, New Jersey, July 14, 2022 - PRESS RELEASE - Orcosa Inc., a clinical-stage life sciences company, announced the appointment of Andrew C. von Eschenbach, Ph.D., former commissioner of the U.S. Food and Drug Administration (FDA), as senior advisor. In his role, Eschenbach will provide strategic counsel on regulatory and public affairs, clinical trial development, and other corporate matters.

“We are honored and privileged to have Dr. von Eschenbach join our team as senior advisor,” said Bryan Ridall, president of Orcosa. “His commitment to improving public health, and his uniquely complete understanding of patients’ needs, and the dynamics of biopharmaceutical research and development are an invaluable complement to our leadership team. We are grateful for his support as we continue to execute on our long-term strategy.”

"As a physician and former FDA Commissioner, I was immediately impressed with Orcosa’s innovative drug delivery platform and thoughtful approach to clinical development and collaboration," Eschenbach said. "The company’s [Rapid Infusion Technology Platform] RITe platform is already demonstrating how it has incredible potential to improve patient outcomes across a range of therapeutic areas—including most critically, in pain management to help reduce opioid usage. I am excited to be part of the Orcosa team, particularly at such a pivotal time in the company’s growth story.”

Eschenbach is widely recognized as a leading physician, surgeon, oncologist, and executive and served as commissioner of the FDA from 2006 to 2009 after being appointed acting commissioner in 2005. In that role, he developed and oversaw the FDA’s Critical Path Initiative, which aimed at improving the regulatory pathway for drugs and medical devices. Eschenbach joined FDA after serving for four years as director of the National Cancer Institute at the National Institutes of Health, and currently serves on the Board of Directors of the Reagan-Udall Foundation for the FDA.

Eschenbach earned a B.S. from St. Joseph’s University and his medical degree from Georgetown University School of Medicine. After completing a residency in urologic surgery at Pennsylvania Hospital in Philadelphia, he was an instructor in urology at the University of Pennsylvania School of Medicine. He completed a Fellowship in Urologic Oncology at the University of Texas M.D. Anderson Cancer Center.